Erasca (ERAS) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Pipeline differentiation and scientific rationale

• Focus on optimizing both potency and pharmacokinetics (PK) to achieve a 'Goldilocks' zone for efficacy and safety in pan-RAS and pan-KRAS inhibitors.

• ERAS-0015 demonstrates 5-10x higher potency than RMC-6236 in preclinical models, requiring lower doses for similar tumor regression.

• Enhanced PK profile includes higher oral bioavailability, longer half-life, and lower clearance, potentially reducing on-target toxicity.

• Preferential biodistribution to tumors may offer a therapeutic window advantage, especially where CypA is overexpressed.

• Pan-KRAS inhibitor ERAS-4001 targets the Switch II Pocket and complements ERAS-0015's mechanism, enabling potential combination strategies.

Clinical progress and early data

• Phase 1 AURORAS-1 study of ERAS-0015 shows multiple partial responses at 8 mg, one-tenth the dose needed for comparator efficacy.

• Safety profile remains favorable with no dose-limiting toxicities and predominantly low-grade adverse events.

• Dose escalation has reached 40 mg, with data on dozens of patients expected in the first half of the year.

• Confirmed partial response observed in a heavily pretreated non-small cell lung cancer patient, aligning with preclinical predictions.

• Patient enrollment includes a balanced distribution across major tumor types, with no single histology dominating.

Development strategy and future plans

• Dose expansion cohorts for ERAS-0015 planned for the second half, focusing on pancreatic and lung cancers as monotherapy and in combinations.

• Differentiation from competitors may be established by achieving a 10% or greater improvement in objective response rate (ORR).

• ERAS-4001 Phase 1 (BOREALIS-1) is ongoing, with data expected in the second half and dose expansions targeted for 2027.

• Both assets may be advanced independently or in combination, with decisions driven by emerging clinical data.

• Combination strategies include pairing with standard of care, investigational agents, or each other, leveraging complementary mechanisms.